tetano
Editor, Senior Moderator
Cardiol Rev
. Sep/Oct 2020;28(5):266-271.
doi: 10.1097/CRD.0000000000000329.
Chloroquine or Hydroxychloroquine for Management of Coronavirus Disease 2019: Friend or Foe?
Lauren A Schluenz[SUP] 1 [/SUP], Gerardo P Ramos-Otero[SUP] 1 [/SUP], James J Nawarskas[SUP] 2 [/SUP]
Affiliations
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to be a threat to the health of many humans across the world as they confront coronavirus disease 2019 (COVID-19). Previous promising in vitro data that emerged after the SARS-CoV outbreak in 2003, along with the emergent need for pharmacologic management strategies in the fight against COVID-19, prompted interest in the use of chloroquine and hydroxychloroquine across the globe. Unfortunately, the in vitro activity of these drugs did not necessarily correlate with most in vivo studies, which showed no consistent efficacy. Safety is also a major concern, with these agents having a known risk of QT prolongation and proarrhythmic effects. In addition, clinical practice guidelines provide no clear consensus on the role of chloroquine or hydroxychloroquine for the management of COVID-19. The United States Food and Drug Administration has declared that the potential benefits of these agents no longer outweigh the possible risks, and unless new emerging information suggests a more favorable risk:benefit ratio, neither chloroquine nor hydroxychloroquine should be recommended for COVID-19 treatment or prevention at this time.
. Sep/Oct 2020;28(5):266-271.
doi: 10.1097/CRD.0000000000000329.
Chloroquine or Hydroxychloroquine for Management of Coronavirus Disease 2019: Friend or Foe?
Lauren A Schluenz[SUP] 1 [/SUP], Gerardo P Ramos-Otero[SUP] 1 [/SUP], James J Nawarskas[SUP] 2 [/SUP]
Affiliations
- PMID: 32769401
- DOI: 10.1097/CRD.0000000000000329
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to be a threat to the health of many humans across the world as they confront coronavirus disease 2019 (COVID-19). Previous promising in vitro data that emerged after the SARS-CoV outbreak in 2003, along with the emergent need for pharmacologic management strategies in the fight against COVID-19, prompted interest in the use of chloroquine and hydroxychloroquine across the globe. Unfortunately, the in vitro activity of these drugs did not necessarily correlate with most in vivo studies, which showed no consistent efficacy. Safety is also a major concern, with these agents having a known risk of QT prolongation and proarrhythmic effects. In addition, clinical practice guidelines provide no clear consensus on the role of chloroquine or hydroxychloroquine for the management of COVID-19. The United States Food and Drug Administration has declared that the potential benefits of these agents no longer outweigh the possible risks, and unless new emerging information suggests a more favorable risk:benefit ratio, neither chloroquine nor hydroxychloroquine should be recommended for COVID-19 treatment or prevention at this time.